[Evaluation of the therapeutic activity of and gastric lesions due to new NSAID versus placebo in patients with osteoarticular diseases].
Oral amtolmetineguacyl 600 mg/day in a single blind comparative trial with placebo carried out in 24 patients suffering from rheumatic disorders of varying severity, reduced statistically all the symptomatology correlated to inflammation. Moreover our results indicate a lack of any gastric problem even in patient with a previous history of intolerance to other NSAIDs.
Delfino
M
M
Dipartimento di Medicina Clinica, Università degli Studi di Roma La Sapienza.
Klesczynski
D
D
Iannetti
A
A
Valente
C
C
Alicicco
E
E
D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use*; D005753:Gastric Mucosa / Q000187:drug effects / Q000503:physiopathology; D005767:Gastrointestinal Diseases / Q000209:etiology* / Q000503:physiopathology; D006801:Humans; D008875:Middle Aged; D010003:Osteoarthritis / Q000188:drug therapy*; D010919:Placebos; D013256:Steroids
D000893:Anti-Inflammatory Agents; D010919:Placebos; D013256:Steroids
Valutazione dell'attività terapeutica e della gastrolesività di un nuovo FANS in confronto a placebo in pazienti con patologie osteoarticolari.